Pharmacokinetic (PK) analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

PK analysis set included all randomized participants who received an injection of study drug, excluding any participants who had a baseline MPA concentration that exceeded 5% of their individual Cmax, had an important protocol deviation that may affect interpretation of their MPA data, or failed to provide at least 1 evaluable post-treatment MPA specimen. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Safety analysis set included all randomized participants who received an injection of study drug.

Concomitant medications included acetic acid derivatives and substances, aminoalkyl ethers, anilides, calcium compounds, other viral vaccines, and propionic acid derivatives etc.

Safety analysis set included all randomized participants who received an injection of study drug.

Vital signs examination included blood pressure, respiration rate, pulse, and body temperature.

Safety analysis set included all randomized participants who received an injection of study drug.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Number analyzed' = participants evaluable at specified timepoint.

Number of participants with overall opinion of vaginal bleeding pattern as acceptable or not acceptable has been reported.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

The PHQ-9 is a participant-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants' responses to each of the 9 questions, as follows: 0=not at all; 1=several days; 2=more than half the days; and 3=nearly every day. The PHQ-9 total score was calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 0 = no depression, 1 to 4=minimal depression, 5 to 9=mild depression, 10 to 14=moderate depression, 15 to 19=moderately severe depression; and 20 to 27=severe depression. Higher scores indicate more severe depression.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Number analyzed' = participants evaluable at specified timepoint.

Safety analysis set included all randomized participants who received an injection of study drug.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Number analyzed' = participants evaluable at specified timepoint.

Ovulation was defined as one or more progesterone measurements ≥ 4.7 ng/mL in Weeks 48, 49, 50, 51 or 52.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

The ISRs included erythema, swelling, pruritus, bleeding, tenderness, bruising, hypopigmentation, atrophy, and injection site pain.

Safety analysis set included all randomized participants who received an injection of study drug.

Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified category.

Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified category.

Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

Safety analysis set included all randomized participants who received an injection of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.